Effects of SGLT2 inhibitor on insulin resistance possbly through the amelioration of glucose toxicity

Effects of SGLT2 inhibitor on insulin resistance possbly through the amelioration of glucose toxicity - SGLT2 inhibitor and insulin resistance

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029064

Enrollment

Registered

2017-09-12

Start date

2017-09-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

SGLT2 inhibitor, Empagliflrozin 10mg/day, is administered for one week.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes from whom informed consent have been obtained and whose HbA1c level are 8% or over.

Exclusion criteria

Exclusion criteria: Patients who are treated by insulin, and who have severe acute metabolic disorder.

Design outcomes

Primary

Measure	Time frame
The change of glucose infusion rate as an marker of insulin sensitivity by the administration of SGLT2 inhibitor for one week	—

Secondary

Measure	Time frame
The change of insulin secretion, daily profile of blood glucose level, body composition, liver function, lipid profile, uric acid, urine volume and urine sugar by the administration of SGLT2 inhibitor for one week	—

Countries

Japan

Contacts

Public ContactYuji Tajiri

Faculty of Internal Medicine, Kurume University Shcool of Medicine Division of Endocrinology and Metabolism

tajiriy@med.kurume-u.ac.jp0942-31-7563

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026